Bristol-Myers Squibb
Projected 2018 sales:
$2.005 billion
2012 sales: $706 million

Yervoy hasn't been around long, but it's made a big impact since its approval in 2011, especially for the ailing Bristol-Myers Squibb ($BMY). With first-quarter results this April revealing a 27% decline in sales--generated by generic competition for blockbuster heart drugs Avapro and Plavix--Yervoy was a bright spot for the company, posting growth of near 50%.

If Yervoy continues on that trajectory, it could surpass the billion-dollar blockbuster mark this year. Bristol-Myers is doing its best to help those numbers along, testing Yervoy paired with therapies from its Big Pharma counterparts. While a Phase I trial testing Yervoy and Roche's ($RHBBY) Zelboraf in melanoma sufferers was stopped in April on account of signs of developing liver toxicity in patients, the drug showed some promise when paired with a white cell booster from Sanofi ($SNY). That tandem kept more than two-thirds of melanoma patients alive after a year of treatment, compared with just half of those who took only Yervoy.

For more:
ASCO confab highlights immunotherapies, 'breakthrough' drugs and small victories
Yervoy-Zelboraf combo trial stopped on toxicity worries
U.K. finally approves Roche's Zelboraf and BMS' Yervoy
Report: Roche's Zelboraf, BMS' Yervoy control their segment


Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.